AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04017832
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
Trial: NCT01266837
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg p.o once daily
Trial: NCT02404298
Drug: IVIg
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01436201
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04017832
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
Trial: NCT00005046
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06259383
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day 1 daily dose of 400 μg/kg oral ivermectin
Trial: NCT03989609
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
Trial: NCT03989609
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
Trial: NCT00041639
Drug: hMN14 (labetuzumab)
RxNorm normalized name: MAb hMN14
DrugBank: Labetuzumab (DB05097)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676596
Drug: K-312 10 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676596
Drug: K-312 25 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04028518
Drug: r-PA
RxNorm normalized name: 89Zr-panitumumab
DrugBank: Zirconium panitumumab Zr-89 (DB19228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.
Trial: NCT04028518
Drug: r-PA
RxNorm normalized name: 89Zr-panitumumab
DrugBank: Zirconium panitumumab Zr-89 (DB19228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.
Trial: NCT04028518
Drug: Alteplase for Injection
RxNorm normalized name: Alteplase for Injection
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h.
Trial: NCT02676596
Drug: K-312 50 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676596
Drug: K-312 100 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676596
Drug: K-312 200 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676596
Drug: K-312 400 mg QD
RxNorm normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001599
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04144036
Drug: Neihulizumab, 6 mg/kg
DrugBank: Neihulizumab (DB16698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Trial: NCT04144036
Drug: Neihulizumab, 9 mg/kg
DrugBank: Neihulizumab (DB16698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Trial: NCT04144036
Drug: Neihulizumab
RxNorm normalized name: Neihulizumab
DrugBank: Neihulizumab (DB16698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
Trial: NCT04450134
Drug: Fexofenadine Hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
Trial: NCT04450134
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonist: 40 mg Famotidine
Trial: NCT04127513
Drug: Ammonium Lactate
RxNorm normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12% ammonium lactate moisturizing cream
Trial: NCT04617847
Drug: WVE-120101
RxNorm normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
Trial: NCT03762928
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
Trial: NCT03762928
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single administration of midazolam 2 mg oral solution
Trial: NCT03762928
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single administration of efavirenz 50 mg capsule
Trial: NCT00005876
Drug: rubitecan
RxNorm normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02767492
Drug: Kenalog
RxNorm normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
Trial: NCT02344290
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet (4 mg) taken once daily, orally with or without food
Trial: NCT01433445
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given 3 times a week, every other week in 28-day cycles.
Trial: NCT01433445
Drug: ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given twice daily in 28-day cycles.
Trial: NCT00865917
Drug: beta-blocker (Metoprolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 95 mg once per day
Trial: NCT00865917
Drug: I(f)-blocker (ivabradine)
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 7.5 mg once per day
Trial: NCT01083966
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS
Trial: NCT00810446
Drug: rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily..
Trial: NCT00224458
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00224458
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04450407
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT01945437
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The magnesium group receive intravenous magnesium sulfate.
Trial: NCT03061656
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1st HDCT
Trial: NCT03061656
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1st HDCT
Trial: NCT03061656
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2nd HDCT
Trial: NCT02623010
Drug: Imbruvica
RxNorm normalized name: Imbruvica
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
Trial: NCT04138836
Drug: BBT-877
RxNorm normalized name: BBT-877
DrugBank: BBT-877 (DB18668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBT-877 oral capsule.
Trial: NCT04138836
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam oral syrup.
Trial: NCT04138836
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral capsule.
Trial: NCT03061656
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2nd HDCT
Trial: NCT05028127
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects will be receiving bimekizumab at pre-specified time-points.
Trial: NCT02548351
Drug: Obeticholic Acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04054973
Drug: L-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6000mg of L-arginine daily for 14 days
Trial: NCT04138836
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole oral capsule.
Trial: NCT03546426
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
Trial: NCT03546426
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU s.c. from day +2 to day +6 after each DC administration
Trial: NCT02845609
Drug: Sialic Acid-Extended Release
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDINGE IG-LIKE LECTIN 8) (HUMAN-MUS MUSCULUS MONOCLONAL AK002 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL AK002 .KAPPA.-CHAIN, DIMER
DrugBank: Lirentelimab (DB16728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug of Sialic acid
Trial: NCT04284930
Drug: Depobupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
Trial: NCT04284930
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
Trial: NCT04092673
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended dosage: 960 mg orally once daily
Trial: NCT04092673
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
Trial: NCT04092673
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose in combination with fulvestrant: 150 mg twice daily
Trial: NCT04092673
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg every 3 weeks
Trial: NCT00545389
Drug: SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00097955
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01618474
Drug: DX
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
Trial: NCT04781361
Drug: Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L
Trial: NCT02244164
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01677364
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm - Induction of labour
Trial: NCT03784040
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Trial: NCT03784040
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Trial: NCT00923182
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00792246
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
Trial: NCT02188472
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V: 2 x 330mg tablets should be taken twice daily
Trial: NCT02188472
Drug: Trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimopan: 2 x 100mg tablets should be taken twice daily
Trial: NCT03177434
Drug: polyethylene glycols (PEG) 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
Trial: NCT03177434
Drug: Lactulose Oral Product
RxNorm normalized name: lactulose Oral Product
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
Trial: NCT02900105
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg (1 tablet) once a day for 4 months
Trial: NCT03885180
Drug: Warfarin Sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extending warfarin anticoagulation
Trial: NCT01188876
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on Day 1 of each 28-day cycle
Trial: NCT01188876
Drug: pralatrexate
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on Day 1 and Day 15 of each 28-day cycle.
Trial: NCT01188876
Drug: Vitamin B12 Injection
RxNorm normalized name: vitamin B12 Injectable Solution
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
Trial: NCT01601327
Drug: Testosterone enanthate (Sustanon 250 mg)
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-eight patients were treated with testosterone enanthate (TE),
Trial: NCT01601327
Drug: Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twenty-five patients were treated with human chorionic gonadotropin (hCG)
Trial: NCT01601327
Drug: Testosteron gel (Testojel 50 mg)
RxNorm normalized name: Testosterone
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty-four patients were treated with testosterone gel (TG).
Trial: NCT04641260
Drug: Fezolinetant
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01486472
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
Trial: NCT01562301
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
Trial: NCT01562301
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
Trial: NCT01562301
Drug: Anvirzel
RxNorm normalized name: Anvirzel
DrugBank: Oleandrin (DB12843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from
Trial: NCT02486640
Drug: Interferon beta-1b (Betaferon, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Trial: NCT00154804
Drug: Paclitaxel, Cisplatin,Surgery, CCRT
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no